Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Mylan Gets EU Rights for Fujifilm Kyowa Kirin Biologics’ Humira Biosimilar
Fujifilm Kyowa Kirin Biologics, a joint venture between Fujifilm and Kyowa Hakko Kirin, said on April 11 that it has granted Mylan exclusive commercialization rights in Europe to FKB327, a biosimilar version of Humira (adalimumab) now pending approval in the…
To read the full story
Related Article
- Japan’s First Humira Biosimilar Could Hit Market as Early as November
May 15, 2020
- Fujifilm Kyowa Kirin, Mylan Bag EU Approval of Humira Biosimilar
September 25, 2018
- Humira Biosimilar Grabs European Panel Backing: Fujifilm Kyowa Kirin/Mylan
July 31, 2018
- EMA Accepts Application for Fujifilm Kyowa Kirin’s Humira Biosimilar
May 23, 2017
BUSINESS
- Toho Subsidiary Suffers Data Breach, HCP Info Exposed
October 20, 2026
- Veritas, Toray Pin Down Hit Compounds for PCSK9 mRNA Drugs
October 20, 2026
- Insmed’s Brinsupri Hits Japan Market for NCFB
October 20, 2026
- Ex-Alfresa Chairman Arata Watanabe Dies at 85
October 20, 2026
- TS Alfresa-Backed Drone Council Inks Pact with Hiroshima
October 19, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…